Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levo-corydalmine hydrochloride
- Development stage
- Unknown
- Lead developer
- Beijing Taizhou Lize Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TLZ-16-CL (levo-corydalmine hydrochloride) is an orally active small molecule drug developed by Beijing Taizhou Lize Pharmaceutical Technology for the treatment of substance withdrawal syndrome and drug addiction, specifically targeting methamphetamine and cocaine dependence. Derived as an active alkaloid from *Corydalis yanhusuo*, levo-corydalmine acts as a multi-target agent, exhibiting antagonistic activity against dopamine D1, D2, and D3 receptors, alongside agonistic activity at the 5-HT1A receptor. It also inhibits NF-κB activation and modulates NMDA and metabotropic glutamate (mGlu1/5) receptors. By blocking dopamine receptors in the brain's reward pathway, TLZ-16-CL suppresses the hyperlocomotion and behavioral sensitization induced by stimulants like methamphetamine, thereby preventing relapse. It is currently in Phase 1 clinical development in China.
- Other names
- L-Corydalmine hydrochloridelevo-corydalminel-corydalminecorydalmine hydrochloride左旋紫堇达明紫堇达明碱
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)GRM1 (Metabotropic glutamate receptor 1)GRM5 (Metabotropic glutamate receptor 5)NMDAR (Glutamate receptor ionotropic, NMDA)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on levo-corydalmine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levo-corydalmine hydrochloride.